BioNxt Solution (CSE: BNXT) (OTC: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery and diagnostic and new active pharmaceutical ingredient investment opportunities, is reporting on its participation at the CPHI pharma conference in Frankfurt, Germany. Earlier this month, BioNxt management attended the event, which is the largest pharma conference in the world; this year’s conference was the first comprehensive in-person CPHI event since the COVID-19 pandemic. The global event is designed to bring together pharma professionals and facilitate networking between premier suppliers and buyers. The conference agenda also includes presentations aimed to help participants discover new pharma trends, hear about groundbreaking ideas and innovations and learn from leading industry experts. The company called CPHI the world’s most important gathering for ingredients, machinery, equipment, technology, package and contract service suppliers, distributors and buyers from the pharma industry. “BioNxt carried out a number of important meetings at CPHI with potential contract manufacturers, products licensees and new product collaborators,” the company stated in the press release. “As BioNxt advances its lead drug-formulation product, a Rotigotine transdermal patch for the treatment of Parkinson’s disease, the company is forging a path towards regulatory approval, commercial production and global distribution. CPHI provided an opportunity to connect and reconnect with several potential strategic parts of its commercial pathway. BioNxt is continually exploring and reviewing new-product opportunities to capitalize on its platform technologies for transdermal and oral dissolvable drug formulations. CPHI also provided an opportunity to follow-up and confirm a promising opportunity to develop a novel oral dissolvable application of an approved active pharmaceutical ingredient for the treatment of a major neurological disorder.”
To view the full press release, visit https://ibn.fm/0JVBE
About BioNxt Solutions Inc.
BioNxt Solutions is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.BioNxt.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
